Keywords
Last Name
Institution

RONALD S WALTERS

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Middleton LP, Feeley TW, Albright HW, Walters R, Hamilton SH. Second-opinion pathologic review is a patient safety mechanism that helps reduce error and decrease waste. J Oncol Pract. 2014 Jul; 10(4):275-80. PMID: 24695900.
      View in: PubMed
    2. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer. 2014; 5(5):351-9. PMID: 24723978.
      View in: PubMed
    3. Walters RS. Opportunities for improvement: experience at one institution. J Natl Compr Canc Netw. 2014 Feb; 12 Suppl 1:S36-9. PMID: 24614051.
      View in: PubMed
    4. Walters RS, Albright HW, Weber RS, Feeley TW, Hanna EY, Cantor SB, Lewis CM, Burke TW. Developing a system to track meaningful outcome measures in head and neck cancer treatment. Head Neck. 2014 Feb; 36(2):226-30. PMID: 23729280.
      View in: PubMed
    5. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5. PMID: 22331946.
      View in: PubMed
    6. Spinks T, Albright HW, Feeley TW, Walters R, Burke TW, Aloia T, Bruera E, Buzdar A, Foxhall L, Hui D, Summers B, Rodriguez A, Dubois R, Shine KI. Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer. 2012 May 15; 118(10):2571-82. PMID: 22045610.
      View in: PubMed
    7. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783.
      View in: PubMed
    8. Tortorella FR, Ewer MS, Douglas-Ntagha PB, Harper G, Walters R, Ecung WB. Developing a transfer center in a tertiary cancer center: streamlining access and communication to accommodate increasing demand for service. J Healthc Manag. 2011 May-Jun; 56(3):199-210; discussion 210-1. PMID: 21714374.
      View in: PubMed
    9. Spinks TE, Walters R, Feeley TW, Albright HW, Jordan VS, Bingham J, Burke TW. Improving cancer care through public reporting of meaningful quality measures. Health Aff (Millwood). 2011 Apr; 30(4):664-72. PMID: 21471487.
      View in: PubMed
    10. Albright HW, Moreno M, Feeley TW, Walters R, Samuels M, Pereira A, Burke TW. The implications of the 2010 Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act on cancer care delivery. Cancer. 2011 Apr 15; 117(8):1564-74. PMID: 21472704.
      View in: PubMed
    11. Feeley TW, Fly HS, Albright H, Walters R, Burke TW. A method for defining value in healthcare using cancer care as a model. J Healthc Manag. 2010 Nov-Dec; 55(6):399-411; discussion 411-2. PMID: 21166323.
      View in: PubMed
    12. Taylor SH, Walters R. Potential impact of tumor registry rule changes for recording inflammatory breast cancer. Cancer. 2010 Jun 1; 116(11 Suppl):2745-7. PMID: 20503404.
      View in: PubMed
    13. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer. 2008 Dec; 8(6):516-21. PMID: 19073507.
      View in: PubMed
    14. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008 Apr 1; 112(7):1455-61. PMID: 18300256.
      View in: PubMed
    15. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'Brien S, Reinke D, Rubino M, Saltz L, Walters RS. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 3:S1-14. PMID: 18377852.
      View in: PubMed
    16. Walters R, Jones LC. Telethinking. Telemed J E Health. 2007 Jun; 13(3):251-5. PMID: 17603827.
      View in: PubMed
    17. Beinart GA, Gonzalez-Angulo AM, Broglio K, Frye D, Walters R, Holmes FA, Gunale S, Booser D, Rosenthal J, Dhingra K, Young JA, Hortobagyi GN. Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2007 Jun; 60(1):61-7. PMID: 17009032.
      View in: PubMed
    18. Gonzalez-Angulo AM, Walters RS, Carpenter RJ, Ross MI, Perkins GH, Gwyn K, Theriault RL. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer. 2004 Oct; 5(4):317-9. PMID: 15507181.
      View in: PubMed
    19. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004 Jun 15; 22(12):2294-302. PMID: 15197190.
      View in: PubMed
    20. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 1; 21(17):3249-54. PMID: 12947059.
      View in: PubMed
    21. Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 1; 97(11):2716-23. PMID: 12767083.
      View in: PubMed
    22. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9. PMID: 12006521.
      View in: PubMed
    23. Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002 Jan-Feb; 8(1):2-9. PMID: 11856154.
      View in: PubMed
    24. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66. PMID: 11458813.
      View in: PubMed
    25. Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 1; 89(11):2195-201. PMID: 11147589.
      View in: PubMed
    26. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21. PMID: 10776969.
      View in: PubMed
    27. Booser DJ, Walters RS, Holmes FA, Hortobagyi GN. Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. Am J Clin Oncol. 2000 Feb; 23(1):40-1. PMID: 10683074.
      View in: PubMed
    28. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34. PMID: 10334527.
      View in: PubMed
    29. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11. PMID: 10370782.
      View in: PubMed
    30. Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol. 1998 Oct; 21(5):442-6. PMID: 9781596.
      View in: PubMed
    31. Walters RS, Holmes FA, Valero V, Esparza-Guerra L, Hortobagyi GN. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am J Clin Oncol. 1998 Aug; 21(4):413-5. PMID: 9708645.
      View in: PubMed
    32. Anderson CM, Walters RS, Hortobagyi GN. Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer. Am J Clin Oncol. 1996 Dec; 19(6):566-8. PMID: 8931672.
      View in: PubMed
    33. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21. PMID: 8874332.
      View in: PubMed
    34. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8. PMID: 8774207.
      View in: PubMed
    35. Theriault RL, Walters RS, Holmes FA, Esparza-Guerra L, Kowal C, Hortobagyi GN. A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer. Cancer Chemother Pharmacol. 1996; 38(3):289-91. PMID: 8646805.
      View in: PubMed
    36. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec; 13(12):2886-94. PMID: 8523051.
      View in: PubMed
    37. Walters RS, Theriault RL, Booser DJ, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer. J Immunother Emphasis Tumor Immunol. 1995 Oct; 18(3):185-7. PMID: 8770774.
      View in: PubMed
    38. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res. 1995 Jul; 1(7):691-7. PMID: 9816034.
      View in: PubMed
    39. Walters RS, Theriault RL, Holmes FA, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer. J Immunother Emphasis Tumor Immunol. 1994 Nov; 16(4):303-5. PMID: 7881639.
      View in: PubMed
    40. Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33(4):313-6. PMID: 8281625.
      View in: PubMed
    41. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9. PMID: 7912522.
      View in: PubMed
    42. Benvenuto JA, Newman RA, Bignami GS, Raybould TJ, Raber MN, Esparza L, Walters RS. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. Invest New Drugs. 1992 Jul; 10(2):113-7. PMID: 1500265.
      View in: PubMed
    43. Walters RS, Theriault RL, Holmes FA, Hortobagyi GN, Esparza L. Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer. Invest New Drugs. 1992 Apr; 10(1):43-4. PMID: 1376723.
      View in: PubMed
    44. Walters RS, Frye D, Buzdar AU, Holmes FA, Hortobagyi GN. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 1992 Jan 15; 69(2):476-81. PMID: 1728377.
      View in: PubMed
    45. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18; 83(24):1797-805. PMID: 1683908.
      View in: PubMed
    46. Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RS, Hortobagyi GN. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol. 1991 Jul; 9(7):1268-74. PMID: 1828499.
      View in: PubMed
    47. Walters R, Kantarjian HM, Keating MJ, Estey EH, Trujillo J, Cork A, McCredie KB, Freireich EJ. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med. 1990 Nov; 89(5):579-87. PMID: 2239977.
      View in: PubMed
    48. Hortobagyi GN, Theriault RL, Frye D, Walters RS, Fraschini G, Tashima CK, Ro JS, Salewski E, Buzdar AU. Pirarubicin in combination chemotherapy for metastatic breast cancer. Am J Clin Oncol. 1990; 13 Suppl 1:S54-6. PMID: 2291460.
      View in: PubMed
    49. Kantarjian HM, Walters RL, Keating MJ, Estey EH, O'Brien S, Schachner J, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer. 1990 Jan 1; 65(1):5-8. PMID: 2293869.
      View in: PubMed
    50. Childs CC, Hirsch-Ginsberg C, Walters RS, Andersson BS, Reuben J, Trujillo JM, Cork A, Stass SA, Freireich EJ, Zipf TF. Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. Leukemia. 1989 Nov; 3(11):777-83. PMID: 2811478.
      View in: PubMed
    51. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989 Aug; 7(8):1071-80. PMID: 2666590.
      View in: PubMed
    52. Kantarjian HM, Walters RS, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer. 1989 Jul 1; 64(1):16-22. PMID: 2659160.
      View in: PubMed
    53. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer. 1989 Mar 1; 63(5):813-7. PMID: 2914287.
      View in: PubMed
    54. Hittelman WN, Agbor P, Petkovic I, Andersson B, Kantarjian H, Walters R, Koller C, Beran M. Detection of leukemic clone maturation in vivo by premature chromosome condensation. Blood. 1988 Dec; 72(6):1950-60. PMID: 3196873.
      View in: PubMed
    55. Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood. 1988 Nov; 72(5):1784-9. PMID: 3052630.
      View in: PubMed
    56. Zander AR, Keating M, Dicke K, Dixon D, Pierce S, Jagannath S, Peters L, Horwitz L, Cockerill K, Spitzer G, et al. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol. 1988 Oct; 6(10):1548-57. PMID: 3049949.
      View in: PubMed
    57. Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988 Aug 15; 62(4):672-6. PMID: 3165046.
      View in: PubMed
    58. Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer. 1988 Aug 15; 62(4):677-82. PMID: 3165047.
      View in: PubMed
    59. Vadhan-Raj S, Kellagher MJ, Keating M, Walters R, Gutterman JU. Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. Behring Inst Mitt. 1988 Aug; (83):119-24. PMID: 2467646.
      View in: PubMed
    60. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 1988 Jul; 2(7):403-12. PMID: 3164797.
      View in: PubMed
    61. Vadhan-Raj S, Buescher S, LeMaistre A, Keating M, Walters R, Ventura C, Hittelman W, Broxmeyer HE, Gutterman JU. Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1988 Jul; 72(1):134-41. PMID: 3291976.
      View in: PubMed
    62. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988 Apr 1; 61(7):1441-6. PMID: 3162181.
      View in: PubMed
    63. Amato R, Kantarjian H, Walters R, Keating M. Rebound peripheral blastosis with subsequent remission during remission induction in a patient with acute promyelocytic leukemia. Cancer. 1988 Feb 15; 61(4):650-3. PMID: 3422175.
      View in: PubMed
    64. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol. 1988 Feb; 6(2):232-8. PMID: 3276823.
      View in: PubMed
    65. Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol. 1988; 22(3):205-10. PMID: 3165725.
      View in: PubMed
    66. Childs CC, Hirsch-Ginsberg C, Culbert SJ, Ahearn M, Reuben J, Trujillo JM, Cork A, Walters RR, Freireich EJ, Stass SA. Lineage heterogeneity in acute leukemia with the t(4;11) abnormality: implications for acute mixed lineage leukemia. Hematol Pathol. 1988; 2(3):145-57. PMID: 3220802.
      View in: PubMed
    67. Lee J, Talpaz M, Walters R, Gutterman JU, Blick M. Aberrant expression of the K-ras proto-oncogene in B-cell malignancies. Hematol Pathol. 1988; 2(4):229-37. PMID: 3075608.
      View in: PubMed
    68. Walters RS, Kantarjian HM, Keating MJ, Talpaz M, Childs CC, McCredie KB, Freireich EJ. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer. 1987 Oct 15; 60(8):1708-12. PMID: 3477315.
      View in: PubMed
    69. Kantarjian H, Walters R. Implications of cytogenetic findings in secondary leukemia. Am J Clin Oncol. 1987 Oct; 10(5):453-6. PMID: 3477944.
      View in: PubMed
    70. Kantarjian HM, Keating MJ, McCredie KB, Walters R, Talpaz M, Smith TL, Freireich EJ. Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia. South Med J. 1987 Oct; 80(10):1228-32. PMID: 3477869.
      View in: PubMed
    71. Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood. 1987 Oct; 70(4):943-7. PMID: 3115339.
      View in: PubMed
    72. Kurzrock R, Shtalrid M, Gutterman JU, Koller CA, Walters R, Trujillo JM, Talpaz M. Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. Br J Haematol. 1987 Sep; 67(1):55-9. PMID: 3478080.
      View in: PubMed
    73. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987 Sep; 83(3):445-54. PMID: 3477958.
      View in: PubMed
    74. Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer. 1987 Jul 15; 60(2):149-55. PMID: 3474052.
      View in: PubMed
    75. Kurzrock R, Kloetzer WS, Talpaz M, Blick M, Walters R, Arlinghaus RB, Gutterman JU. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood. 1987 Jul; 70(1):233-6. PMID: 2885048.
      View in: PubMed
    76. Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol. 1987 May; 5(5):710-21. PMID: 3553435.
      View in: PubMed
    77. Kantarjian HM, Keating MJ, Walters RS, Smith TL, McCredie KB, Freireich EJ. Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer. 1987 Apr 1; 59(7):1258-63. PMID: 3469011.
      View in: PubMed
    78. Dicke KA, Jagannath S, Walters RS, Horwitz LJ, Spitzer G. The role of autologous bone marrow transplantation in acute leukemia. Ann N Y Acad Sci. 1987; 511:468-72. PMID: 3326476.
      View in: PubMed
    79. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res. 1987; 11(2):119-33. PMID: 3469482.
      View in: PubMed
    80. Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T, McCredie KB, Freireich EJ. Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol. 1987; 78 Suppl 1:120-6. PMID: 3124434.
      View in: PubMed
    81. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986 Dec; 4(12):1748-57. PMID: 3783201.
      View in: PubMed
    82. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Smith TL, Talpaz M, Beran M, Cork A, Trujillo JM, Freireich EJ. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer. 1986 Nov 1; 58(9):2023-30. PMID: 3463397.
      View in: PubMed
    83. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Bodey GP, Freireich EJ. Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. Cancer. 1986 Oct 15; 58(8):1603-8. PMID: 3463390.
      View in: PubMed
    84. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med. 1986 Sep; 81(3):387-94. PMID: 3463209.
      View in: PubMed
    85. Kantarjian HM, Keating MJ, Walters RS, Beran M, McLaughlin P, McCredie KB, Freireich EJ. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer. 1986 Aug 15; 58(4):924-7. PMID: 3719557.
      View in: PubMed
    86. Jones PG, Rolston KV, Fainstein V, Elting L, Walters RS, Bodey GP. Aztreonam therapy in neutropenic patients with cancer. Am J Med. 1986 Aug; 81(2):243-8. PMID: 3526885.
      View in: PubMed
    87. Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT, Cork A, Trujillo JM, Freireich EJ. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med. 1986 May; 80(5):789-97. PMID: 3458366.
      View in: PubMed
    88. Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985 Dec; 66(6):1326-35. PMID: 3864497.
      View in: PubMed
    89. Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104. PMID: 3859935.
      View in: PubMed
    90. Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Dalton WT, Hittleman W, Freireich EJ. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J Clin Oncol. 1985 Jun; 3(6):793-8. PMID: 3859586.
      View in: PubMed
    91. Estey EH, Keating MJ, Smith TL, McCredie KB, Legha SS, Walters RS, Bodey GP, Freireich EJ. Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. J Clin Oncol. 1984 Feb; 2(2):102-6. PMID: 6583328.
      View in: PubMed
    92. Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med. 1983 Dec; 99(6):789-92. PMID: 6580836.
      View in: PubMed
    93. Phase I-II study of aziridinylbenzoquinone in acute leukemia.
    94. Assessing compliance with established Pneumonia Core Measures at a comprehensive cancer center. Journal for healthcare quality : official publication of the National Association for Healthcare Quality. 37:232-244.
    95. 60 Years of survival outcomes at the university of Texas MD Anderson cancer center.
    96. Value-Based Breast Cancer Care. Annals of Surgical Oncology. 1-6.
    WALTERS's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description